Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    high point clinical trials center cigarette

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03379740
Recruitment Status : Completed
First Posted : December 20, 2017
Last Update Posted : December 20, 2017
Sponsor:
Information provided by (Responsible Party):
Philip Morris Products S.A.

Brief Summary:
This is a single-center, open-label, concentration-ranging study to evaluate the nicotine PK profile and PD effects in healthy adult experienced users of closed tank/cartridge e-cigarettes using four different variants of P4M3 (nicotine concentration of 1.7%, 1.7% with 1.1% lactic acid [LA], 3% with 1.1% LA, and 4% with 2% LA) or their own e-cigarettes.

Condition or disease Intervention/treatment Phase
Vaping Nicotine Absorption Other: E-cigarette Other: P4M3-1.7% Other: P4M3-1.7%LA Other: P4M3-3%LA Other: P4M3-4%LA Not Applicable

Detailed Description:

The goal of the study is to evaluate the nicotine concentration profiles and derived PK parameters, subjective effects, behavioral parameters, including puffing topography parameters of P4M3 with four different variants of P4M3, in experienced e-cigarette users after a single-use experience with fixed puffing and after ad libitum use of P4M3.

Four variants of P4M3 will be evaluated together with subjects' own e-cigarettes to evaluate the relationship between the e-liquid composition (nicotine concentrations and presence of lactic acid) and the amount of nicotine absorbed, the speed of absorption, and the puffing topography.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: This is an open-label study; however the site (except the pharmacy staff preparing the IPs for administration) will be masked to the randomization sequences until they are assigned. Subjects will not be informed of the complete sequence to which they have been assigned to receive the P4M3 products.
Primary Purpose: Other
Official Title: A Single-center, Open-label, Concentration-ranging Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of the P4M3 Variants
Actual Study Start Date : July 11, 2017
Actual Primary Completion Date : August 14, 2017
Actual Study Completion Date : December 1, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Product Exposure Sequence 1

Subjects will be randomized to follow a sequence of product exposure comprised of :

E-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA

Other: E-cigarette
Subject's own e-cigarette

Other: P4M3-1.7%
P4M3 e-liquid concentration of 1.7% nicotine without lactic acid

Other: P4M3-1.7%LA
P4M3 e-liquid concentration of 1.7% nicotine with lactic acid

Other: P4M3-3%LA
P4M3 e-liquid concentration of 3% nicotine with lactic acid

Other: P4M3-4%LA
P4M3 e-liquid concentration of 4% nicotine with lactic acid

Experimental: Product Exposure Sequence 2

Subjects will be randomized to follow a sequence of product exposure comprised of :

E-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA

Other: E-cigarette
Subject's own e-cigarette

Other: P4M3-1.7%
P4M3 e-liquid concentration of 1.7% nicotine without lactic acid

Other: P4M3-1.7%LA
P4M3 e-liquid concentration of 1.7% nicotine with lactic acid

Other: P4M3-3%LA
P4M3 e-liquid concentration of 3% nicotine with lactic acid

Other: P4M3-4%LA
P4M3 e-liquid concentration of 4% nicotine with lactic acid




Primary Outcome Measures :
  1. Plasma nicotine concentration versus time profile [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure total and background-corrected plasma nicotine concentration versus time profiles from 60 minutes of ad libitum use.

  2. Peak plasma nicotine concentration [cCpeak] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure background-corrected peak plasma nicotine concentration [cCpeak] from 60 minutes of ad libitum use.

  3. Time to peak plasma nicotine concentration [tpeak] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure the time to peak plasma nicotine concentration [tpeak] from 60 minutes of ad libitum use.

  4. Background-corrected trough plasma nicotine concentration [cCtrough] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure background-corrected trough plasma nicotine concentration [cCtrough] from 60 minutes of ad libitum use.

  5. Background-corrected average of plasma nicotine concentration [cCaverage] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure background-corrected average of plasma nicotine concentration between 0 to 1 hour [cCaverage] from 60 minutes of ad libitum use.


Secondary Outcome Measures :
  1. Total and background-corrected plasma nicotine concentration versus time profiles [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure the total and background-corrected plasma nicotine concentration versus time profiles of the P4M3 variants and subjects' own e-cigarette from the fixed puffing regimen.

  2. Background-corrected maximum plasma concentration [cCmax] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure the background-corrected maximum plasma concentration [cCmax] of the P4M3 variants and subjects' own e-cigarette from the fixed puffing regimen.

  3. Time to the maximum concentration [tmax] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure the time to the maximum concentration [tmax] of the P4M3 variants and subjects' own e-cigarette from the fixed puffing regimen.

  4. Background-corrected area under the concentration-time curve [cAUC(0-4h)] [ Time Frame: From Day -1 (baseline) to Day 4 ]
    To measure the background-corrected area under the concentration-time curve, which is above the corrected baseline from the start of product use to 4 hours [cAUC(0-4h)], of the P4M3 variants and subjects' own e-cigarette from the fixed puffing regimen.

  5. Subjective effects of P4M3 use [ Time Frame: From Day -1 (baseline) to Day 4 ]
    Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) within 60 minutes after the ad libitum use session.

  6. Craving for an electronic cigarette [ Time Frame: From Day -1 (baseline) to Day 4 ]
    Measured on on a Visual Analogue Scale (VAS) of 0 (no craving) to 10 (strong craving), before and after the fixed puffing regimen and ad libitum use period.

  7. Sensory parameters [ Time Frame: From Day 1 to Day 4 ]
    Measured with a Sensory Questionnaire (SQ) within 60 minutes after each fixed puffing regimen and ad libitum use period.

  8. Human puffing topography (HPT) of the P4M3 variants and the subjects' own e-cigarette [ Time Frame: From Day -1 (baseline) to Day 4 ]
    Measure per-puff parameters and per-product use experience parameters of the P4M3 variants and the subjects' own e-cigarette from the fixed puffing regimen and the 60 minutes ad libitum use.

  9. Safety and tolerability during the study, measured by incidence of adverse events (AEs) and serious adverse events (SAEs); frequency of AEs and SAEs. [ Time Frame: Study duration (up to 5 weeks) ]
    AEs and SAEs will be collected through spontaneous reporting or by the use of consistent, open, non-directive questions from the investigational site collaborators.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject has signed the informed consent form (ICF) and is able to understand the information provided in the ICF.
  • Subject is 21 to 65 years of age, inclusive, at the Screening Visit.
  • Subject is a former daily cigarette smoker who smoked at least 100 cigarettes or more in his/her life and ceased smoking at least 3 months prior to the Screening Visit.
  • Subject has been using a commercially available, nicotine-containing closed tank/cartridge e-cigarette daily for at least 3 months prior to the Screening Visit.
  • Subject has a urine cotinine test ≥200 ng/mL at the Screening Visit and Admission.

Exclusion Criteria:

  • Subject has a clinically relevant disease which requires medication which as per the judgment of the Investigator would jeopardize the safety of the subject.
  • Subject has abnormal renal function test result or subject with a creatinine clearance <60 mL/minute at the Screening Visit, confirmed on repeat testing.
  • Subject has elevated liver function test results at the Screening Visit.
  • Subject has bilirubin >1.5X ULN at the Screening Visit.
  • Subject has FEV1/FVC <0.7 and FEV1 <80% predicted value at post-bronchodilator spirometry at the Screening Visit.
  • Subject has asthma condition at the Screening Visit.
  • Subject has received medication within 14 days or within 5 half-lives of the drug (whichever is longer) prior to Admission, which has an impact on cytochrome P450 (CYP) 2A6 activity.
  • Subject has a carbon monoxide (CO) breath test ≥ 10 ppm at the Screening Visit or Admission.
  • Subject has a body mass index (BMI) <18.5 kg/m2 or BMI ≥35 kg/m2 at the Screening Visit.
  • Subject has a positive serology test for human immunodeficiency virus (HIV) 1/2, hepatitis B, or hepatitis C at the Screening Visit.
  • Subject has clinically significant ECG findings at the Screening Visit.
  • Subject has participated in a clinical study within 3 months prior to the Screening Visit.
  • Subject smokes cigarettes or uses other tobacco products.
  • Female subject of childbearing potential who is pregnant or breastfeeding.
  • Female subject of childbearing potential who does not agree to use an acceptable method of effective contraception..

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03379740


Locations
Layout table for location information
United States, North Carolina
High Point Clinical Trials Center
High Point, North Carolina, United States, 27265
Sponsors and Collaborators
Philip Morris Products S.A.
Investigators
Layout table for investigator information
Study Chair: Christelle Haziza, PhD Philip Morris Products S.A.
Principal Investigator: Jonathan Austin, MD High Point Clinical Trials Center

Layout table for additonal information
Responsible Party: Philip Morris Products S.A.
ClinicalTrials.gov Identifier: NCT03379740     History of Changes
Other Study ID Numbers: P4M3-PK-02-US
First Posted: December 20, 2017    Key Record Dates
Last Update Posted: December 20, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Philip Morris Products S.A.:
Reduced risk product

Additional relevant MeSH terms:
Layout table for MeSH terms
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action